HC Wainwright lowered shares of Proteon Therapeutics Inc (NDAQ:PRTO) from a buy rating to a neutral rating in a research report report published on Friday morning. HC Wainwright currently has $3.00 price target on the stock.
Shares of Proteon Therapeutics (NDAQ:PRTO) traded down 5.71% on Friday, hitting $1.65. 231,877 shares of the stock traded hands. Proteon Therapeutics has a 1-year low of $1.40 and a 1-year high of $11.63. The stock has a 50 day moving average of $1.87 and a 200-day moving average of $5.83. The stock’s market cap is $27.38 million.
var userip;Your IP Address: document.write(userip);
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.